Market Overview

Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study

Related BMY
Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients
Bristol-Myers/AbbVie Cancer Drug Gets Priority Review (Zacks)

Squibb Company (NYSE: BMY) and AbbVie (NYSE: ABBV) today announced updated efficacy and safety data from a small,
randomized Phase 2, open-label study in patients with previously-treated
multiple myeloma that evaluated two doses of the investigational
monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination
with lenalidomide and low-dose dexamethasone. In the 10 mg/kg arm
(N=36), which is the dose used in the ongoing Phase 3 trials, median
progression-free survival (PFS), or the time without disease
progression, was 33 months after a median follow-up of 20.8 months (95%
CI: 14.9-NA) and the objective response rate (ORR) was 92%. As
previously reported, median PFS was 18 months in the 20 mg/kg arm (N=37)
after a median follow-up

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (ABBV)

Get Benzinga's Newsletters